Loss injections may reduce risk of dozens of diseases

Another evidence of the huge health effect of weight loss – far beyond weight loss: A new and comprehensive research of the US military reveals that the drugs Vigobobi, Mangero and Ozmitz affect 175 medical conditions, including a risk reduction in many diseases, including cardiovascular disorders, Alzheimer’s and addictions. The study was published in the journal Nature Medicine at his last age.

According to Ziad al-Ali One, one of the research authors and the head of the research field in the US military veterans – “We tend to think that drugs are for a single effect, but in practice they create a complex network of different effects.”

The study shows that the GLP1 slimming drugs that are currently approved for type 2 diabetes, obesity and cardiovascular risks may also benefit from conditions such as Alzheimer’s disease and addiction to substances such as alcohol and cannabis.

As part of the study, patients who received GLP-1 drugs were compared to patients treated with old diabetes, as well as a diabetes control group. The findings pointed to connections between the use of drugs and a decrease in risk of cardiovascular problems, kidney disease and liver disease. However, side effects such as gastric acidity – reflux, headaches and pancreatitis were also identified.

One of the surprising findings was the possible connection between drugs and blood clotting improvement, respiratory function and infections. In the meantime, the study found a decrease in suicidal thoughts among drug users, contrary to the concerns that were initially. Dr. Wolkov’s shotThe National U.S. Institute Director has noted that GLP-1 drugs may reduce stress response, as observed in animal models.

The GLP-1 family has been tremendous in recent years. In a 2024 survey, one reported in all eight adults in the US that he tried or uses these drugs. However, their high cost, about $ 1,000 a month, and their partial insurance coverage, raise questions about accessibility and equality. The 50% injections from the beginning of January, as part of the complementary insurance.

However, some of the findings aroused question marks. For example, in some participants, arthritis is reported, although weight loss itself is supposed to relieve arthritis symptoms. Experts said these symptoms may have been due to the fact that the research population was made up of older men who suffered from a variety of medical problems.

Vigobobi of Novo Nordisk and Maangero belongs to a group of drugs based on the imaging of natural hormones in the body, which control appetite and provokes a sense of satiety. The drugs work on receptors in the central nervous system, thus reducing hunger and helping to significantly reduce weight. Beyond their ability to effectively reduce weight, the injections have already shown the ability to reduce the risk of heart attacks and strokes, and even treat sleep apnea, a dangerous condition that increases the risk of morbidity and mortality.